Cart
sales@molnova.com
Danirixin
CAS No. 954126-98-8
Danirixin( GSK-1325756 )
Catalog No. M16816 CAS No. 954126-98-8
Danirixin (GSK-1325756) is a high-affinity, selective and reversible CXCR2 antagonist (IC50=12.5 nM, CXCL8).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 104 | In Stock |
|
| 5MG | 107 | In Stock |
|
| 10MG | 180 | In Stock |
|
| 25MG | 335 | In Stock |
|
| 50MG | 523 | In Stock |
|
| 100MG | 737 | In Stock |
|
| 200MG | 1014 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDanirixin
-
NoteResearch use only, not for human use.
-
Brief DescriptionDanirixin (GSK-1325756) is a high-affinity, selective and reversible CXCR2 antagonist (IC50=12.5 nM, CXCL8).
-
DescriptionDanirixin (GSK-1325756) is a high-affinity, selective and reversible CXCR2 antagonist (IC50=12.5 nM, CXCL8); blocks the CD11b upregulation with pIC50 of 6.05 and 6.3, respectively, in rat and human whole-blood studies; blocks the influx of neutrophils into the lung in vivo in rats following aerosol lipopolysaccharide (ED50=1.4 mg/kg); orally active.COPD Phase 2 Clinical(In Vitro):Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine.
-
In VitroDanirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine.
-
In Vivo——
-
SynonymsGSK-1325756
-
PathwayGPCR/G Protein
-
TargetChemokine Receptor
-
RecptorCXCL8-CXCR2
-
Research AreaInflammation/Immunology
-
IndicationCOPD
Chemical Information
-
CAS Number954126-98-8
-
Formula Weight441.9041
-
Molecular FormulaC19H21ClFN3O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 8 mg/mL
-
SMILESClC(C(S([C@H]1CCCNC1)(=O)=O)=C2O)=CC=C2NC(NC3=CC=CC(F)=C3C)=O
-
Chemical NameUrea, N-[4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl]-N'-(3-fluoro-2-methylphenyl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bloomer JC, et al. Eur J Pharm Biopharm. 2017 Apr 3. pii: S0939-6411(16)31009-8.
2. Miller BE, et al. BMC Pharmacol Toxicol. 2015 Jun 20;16:18.
3. Busch-Petersen J, et al. J Pharmacol Exp Ther. 2017 Aug;362(2):338-346.
molnova catalog
related products
-
SB 265610
A potent, selective, reversible CXCR2 antagonist with with Kd of 3.48 nM.
-
MK-0812 succinate
A potent CCR2 specific antagonist that blocks MCP-1 mediated response with an IC50 of 3.2 nM.
-
SX-517
A potent, specific, noncompetitive dual CXCR1 and CXCR2 antagonist with IC50 of 38 nM (vs. CXCL1) and 36 nM (vs. CXCL8), respectively.
